Skip to main content

Table 3 High Scoring Pairs of Interest from TF Model

From: Predicting clinically promising therapeutic hypotheses using tensor factorization

Target High Scoring Indication in Clinical Pipeline (Phase*) PubmedID Related Approved Indication (Total Approved Indications)
ABCC8 Glucose Intolerance (III) 23903354 Diabetes Mellitus (1)
ADRB1 Cachexia (II) 20426789 Ischemia (13)
ADRB2 Hypoglycemia (I) 22013013 Glaucoma (15)
ADRB2 Myocardial Infarction (III) 26692153 Heart Failure (15)
AGTR1 Hypercholesterolemia (III) 12117739 Hyperlipidemias (7)
CYP3A4 Hepatitis C (II) 20938912 HIV Infections (1)
IL2 Behcet Syndrome (II) 26654556 Graft Rejection (1)
IL6 Waldenstrom Macroglobulinemia (I) 26238488 Giant Lymph Node Hyperplasia (1)
IL6 Arthritis, Psoriatic (II) 27789987 Giant Lymph Node Hyperplasia (1)
OPRM1 Schizophrenia (III) 27397309 Migraine Disorders (22)
RYR1 Muscular Dystrophy, Duchenne (I) 26793121 Malignant Hyperthermia (1)
SERPINC1 Hemophilia (II) 27099538 Blood Coagulation Disorders (16)
TNFSF11 Hypercalcemia (II) 27904108 Osteoporosis (1)
VDR Alopecia (I) 27932380 Keratosis (9)
VDR Cachexia (I) 22497530 Chronic Kidney Failure (9)
  1. New indications of approved targets in clinical trials (Phase* as of May 27, 2016) that have the highest probability of eventual clinical success as measured by the tensor factorization model. The full list is available in the supplement. For illustrative purposes, we list a related indication approved for assets for each target